Stavudine plus lamivudine in advanced human immunodeficiency virus disease: A short-term pilot study

Journal of Infectious Diseases

Volumn 176, Issue 5, 1997, Pages 1156-1160

  Rouleau, Danielle ^b   Conway, Brian ^b   Raboud, Janet ^b   Rae, Sandra ^b   Fransen, Signe ^b   Shillington, Andrew ^b   Zala, Carlos ^b   O'Shaughnessy, Michael V ^b   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0030780590     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514107     Document Type: Article

References (16)

1. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
2. Hammer SM, Katzenstein DA, Hugues MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
3. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
4. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996;276:118-25.
5. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-expericnced patients. JAMA 1996;276:111-7.
6. CAESAR Coordinator Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
7. + cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992;165:352-63.
8. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995;9:159-63.
9. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
10. Saag MS, Holodnty M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
11. Katzenstein DA, Hammer SM, Hugues MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
12. Ho DD. Viral counts count in HIV infection. Science 1996;272:1124-5.
13. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV Infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-54.
14. Coates JAV, Cammack N, Jenkinson HJ, et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733-9.
15. Schinazi RF, Chu CK, Peck A, et al. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 1992;36:672-6.
16. Van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase 1 study. AIDS 1992;6:1471-5.